{
  "docId": "019de077-691b-72c2-80d2-a28de652ce70",
  "docSlug": "7b833127c4e1241e21c155446b1ba76b",
  "documentTitle": "MindMed | Investor Presentation Deck | 42 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 42,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide uses a 3x2 matrix structure to contrast clinical efficacy, market opportunity, and current treatment limitations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-691b-72c2-80d2-a28de652ce70/9",
  "deckHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70",
  "deckJsonHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70.json",
  "deckAnchorHref": "/decks/019de077-691b-72c2-80d2-a28de652ce70#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.72,
        "x": 0.24,
        "y": 0.16
      },
      "kind": "callout",
      "text": "Potential Best-in-Class Therapy with Novel MOA",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be1871dd-f62d-4e7b-b34f-2728a603ccc5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Based on results from Phase 2b Study MMED008... 4. GAD: generalized anxiety disorder; MDD: major depressive disorder...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7ca5e0a-b993-4027-a7f8-f404304a14d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "table",
      "text": "Matrix comparing GAD and MDD across Preliminary Clinical Evidence, Large Market Opportunities, and Significant Need for New Treatments.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e4b5d6f5-c964-405a-8ea3-b6e69fb7ce41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "MM120: Potential to Address Large Unmet Needs in Major Brain Health Disorders",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc92a998-870c-46e2-bb63-67f42102b6e8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "1b5fe7aa-e83c-42f1-9dc2-b700c9a75846",
      "evidence": "table/data: Matrix comparing GAD and MDD across Preliminary Clinical Evidence, Large Market Opportunities, and Significant Need for New Treatments.",
      "confidence": 0.8
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "8aa03a82-68f4-4b59-b41d-33c4c03f1f9e",
      "evidence": "Potential Best-in-Class Therapy with Novel MOA",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "matrix-nxn",
      "slug": null,
      "matchId": "7f2b97f0-060f-4cb7-8072-dbf36115465a",
      "evidence": "3x2 grid comparing clinical, market, and need factors across two disease states.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "f03f5f70-fbfa-4fd3-bbe0-8920a77d58d6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The problem statement is clearly presented on page 9, highlighting the need for novel therapies in brain health.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6e258645-fc1b-4e40-b71b-ce1ca3ac87d4",
      "evidence": "The problem statement and solution sections create a loop that emphasizes the cost of inaction and the potential benefits of MM120.",
      "position": 0,
      "objective": "Highlighting the need for novel therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 42,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6a4562d9-e1ba-4048-9ae4-0523b32c6d36",
      "evidence": "The document follows the golden circle framework, starting with the company's vision (why) and presenting its approach (how) and solution (what).",
      "position": 1,
      "objective": "Presenting the company's vision and approach",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}